semaglutide advisory committee Getting to the heart of GLP-1 Profile of semaglutide in the

A large cardiovascular outcomes trial found that higher proportions of tirzepatide recipients reported vomiting, diarrhea, and nausea compared to those taking a selective GLP-1RA

Under controlled trial conditions with strict administration adherence, oral and injectable semaglutide produce comparable weight loss

Its administration decreased levels of 4-hydroxynonenal (a product of lipid peroxidation) in patients with cardiomyopathy (Malig et al., 2016)

Tirzepatide is the world's first dual GLP-1/GIP receptor agonist

After 7 months, the offering is generating $100M in run-rate revenue across 100k incremental subscribers